Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.
- 1 January 2007
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (7), 1423-1425
- https://doi.org/10.1080/10428190701361851
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single centerLeukemia & Lymphoma, 2007
- VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemiaAmerican Journal of Hematology, 2006
- Bortezomib is effective in primary plasma cell leukemiaLeukemia & Lymphoma, 2006
- Tumor Lysis Syndrome After Bortezomib Therapy for Plasma Cell LeukemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomibAnnals of Hematology, 2005
- Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and DifferencesSeminars in Hematology, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Bortezomib is an efficient agent in plasma cell leukemiasInternational Journal of Cancer, 2004
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Treatment Approaches for Relapsing and Refractory Multiple MyelomaActa Oncologica, 2000